Literature DB >> 2972266

Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis.

A M Scanu1.   

Abstract

Lipoprotein(a) (Lp[a]) represents a class of plasma lipoprotein particles that have overall characteristics similar to low-density lipoproteins but distinct from them by having apolipoprotein B100 linked to apolipoprotein(a) by disulfide bridge(s). This protein has recently been shown to have a striking amino acid sequence homology with plasminogen, a serine protease zymogen that on activation to plasmin promotes the conversion of fibrinogen to fibrin. The high incidence of Lp(a) in the plasma of patients with cardiovascular disease has been noted by many investigators. The new knowledge being rapidly acquired on the structure of Lp(a) should facilitate the understanding of the mechanism of its atherogenicity and perhaps shed light on its possible physiologic role.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972266

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

Review 1.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 2.  Lipoprotein(a): searching for a function.

Authors:  P C Harpel; M Poon; X Zhang; M B Taubman
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

3.  Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay.

Authors:  R W Evans; S S Sankey; B A Hauth; K Sutton-Tyrrell; M I Kamboh; L H Kuller
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

4.  High lipoprotein (a) levels as a thrombogenic risk factor in Behçet's disease.

Authors:  A Orem; O Değer; O Memiş; K Calişkan; G Cimşit
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

Review 5.  The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events.

Authors:  A M Scanu
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

6.  Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).

Authors:  F Hartgens; G Rietjens; H A Keizer; H Kuipers; B H R Wolffenbuttel
Journal:  Br J Sports Med       Date:  2004-06       Impact factor: 13.800

Review 7.  Lipoprotein(a) and its role in occlusive vascular disease.

Authors:  M Tennant; J K McGeachie
Journal:  Ann R Coll Surg Engl       Date:  1993-01       Impact factor: 1.891

8.  Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin.

Authors:  P C Harpel; B R Gordon; T S Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 9.  Lipoprotein(a): nonhuman primate models.

Authors:  K Makino; A M Scanu
Journal:  Lipids       Date:  1991-09       Impact factor: 1.880

10.  Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.

Authors:  Christoph Waldeyer; Nataliya Makarova; Tanja Zeller; Renate B Schnabel; Fabian J Brunner; Torben Jørgensen; Allan Linneberg; Teemu Niiranen; Veikko Salomaa; Pekka Jousilahti; John Yarnell; Marco M Ferrario; Giovanni Veronesi; Paolo Brambilla; Stefano G Signorini; Licia Iacoviello; Simona Costanzo; Simona Giampaoli; Luigi Palmieri; Christa Meisinger; Barbara Thorand; Frank Kee; Wolfgang Koenig; Francisco Ojeda; Jukka Kontto; Ulf Landmesser; Kari Kuulasmaa; Stefan Blankenberg
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.